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OBJECTIVE—Leukocyte inﬁltration of adipose is a critical deter-
minant of obesity-related metabolic diseases. Fractalkine (CX3CL1)
and its receptor (CX3CR1) comprise a chemokine system involved
in leukocyte recruitment and adhesion in atherosclerosis, but its
role in adipose inﬂammation and type 2 diabetes is unknown.
RESEARCH DESIGN AND METHODS—CX3CL1 mRNA and
protein were quantiﬁed in subcutaneous adipose and blood during
experimental human endotoxemia and in lean and obese human
adipose. CX3CL1 cellular source was probed in human adipocytes,
monocytes, and macrophages, and CX3CL1-blocking antibodies
were used to assess its role in monocyte-adipocyte adhesion. The
association of genetic variation in CX3CR1 with metabolic traits
was determined in a community-based sample. Finally, plasma
CX3CL1 levels were measured in a case-control study of type 2
diabetes.
RESULTS—Endotoxemia induced adipose CX3CL1 mRNA (32.7-
fold, P , 1 3 10
25) and protein (43-fold, P = 0.006). Obese
subjects had higher CX3CL1 levels in subcutaneous adipose
compared with lean (0.420 6 0.387 vs. 0.228 6 0.187 ng/mL,
P = 0.04). CX3CL1 was expressed and secreted by human adi-
pocytes and stromal vascular cells. Inﬂammatory cytokine in-
duction of CX3CL1 in human adipocytes (27.5-fold mRNA and
threefold protein) was completely attenuated by pretreatment
with a peroxisome proliferator–activated receptor-g agonist. A pu-
tative functional nonsynonymous single nucleotide polymorphism
(rs3732378) in CX3CR1 was associated with adipose and meta-
bolic traits, and plasma CX3CL1 levels were increased in patients
with type 2 diabetes vs. nondiabetics (0.506 6 0.262 vs. 0.422 6
0.210 ng/mL, P , 0.0001).
CONCLUSIONS—CX3CL1-CX3CR1 is a novel inﬂammatory
adipose chemokine system that modulates monocyte adhesion
to adipocytes and is associated with obesity, insulin resistance,
and type 2 diabetes. These data provide support for CX3CL1 as
a diagnostic and therapeutic target in cardiometabolic disease.
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dipose tissue inﬂammation plays a central role
in obesity-related metabolic and cardiovascular
complications, including type 2 diabetes (1). A
key event in adipose inﬂammation is recruitment
of leukocytes (2–4), which produces local inﬂammatory
signaling molecules creating a feed-forward cycle of adi-
pose and systemic inﬂammation and insulin resistance.
Upregulation of adipose chemokines has emerged as an
important mechanism in leukocyte recruitment, early adi-
pose inﬂammation, and insulin resistance in obesity. In par-
ticular, monocyte chemotactic protein-1 (MCP-1 or CCL2)
and its receptor CCR2 are signiﬁcant contributors to ad-
ipose macrophage recruitment and insulin resistance in
obesity (3,5). However, adverse metabolic consequences
are only partially attenuated in CCL2- or CCR2-deﬁcient
mice, suggesting involvement of additional chemokine path-
ways (6). Several other CC and CXC chemokines impli-
cated in recruitment of inﬂammatory T-cells and monocytes
(4), including CCL5 (also called RANTES [regulated on
activation, normal T-cell expressed and secreted]), CXCL8
(interleukin-8) and CXCL 10 (interferon g-induced protein)
are increased in obesity in rodents (7). However, which
chemokines play a causal role in human adipose inﬂam-
mation and its metabolic complications remains uncertain.
Fractalkine (CX3CL1), a chemokine that signals through
a single known receptor (CX3CR1), is implicated in re-
cruitment and adhesion of both monocytes and T-cells in
atherosclerosis, rheumatologic disorders, and HIV-1 (8).
CX3CL1, the sole CX3C chemokine, is unique among che-
mokines in having both soluble and transmembrane forms,
the latter of which mediates ﬁrm cell adhesion (9). Many
leukocyte subtypes, in particular monocytes, T-cells, and
NK cells, express CX3CR1 (9,10), a G-protein–coupled re-
ceptor that promotes leukocyte activation and survival (11).
In fact, CX3CR1 is required for vascular recruitment of in-
ﬂammatory monocytes and development of macrophage-
rich atherosclerotic lesions (12,13). Knowledge of CX3CL1’s
role in adipose biology is limited but recent data suggest
that CX3CL1 is expressed in adipocytes and that CX3CR1
signaling in macrophages is downregulated by peroxisome
proliferator–activated receptor (PPAR)-g agonists (14). Fur-
thermore, the fact that manipulation of the CX3CL1/CX3CR1
system can modulate chronic inﬂammatory diseases, in-
cluding atherosclerosis, independent of CCL2/CCR2 (15)
suggests that this may also occur in adipose inﬂammation
and its complications.
Recently, using microarray of adipose mRNA during
experimental endotoxemia, we found that CX3CL1 is one
of several genes markedly upregulated in human adipose
by in vivo inﬂammation (16). Here, we deﬁne CX3CL1 as
a novel inﬂammatory adipose chemokine in humans. First,
adipose CX3CL1 is increased in obesity as well as in
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ORIGINAL ARTICLEevoked adipose inﬂammation. Second, CX3CL1 promotes
monocyte adhesion to human adipocytes. Third, genetic
variation in CX3CR1 is associated with metabolic traits in
humans while plasma CX3CL1 levels are higher in type 2
patients with diabetes compared with control subjects.
RESEARCH DESIGN AND METHODS
Clinical studies. Each clinical study was performed with the approval of the
University of Pennsylvania (UPenn) Institutional Review Board after written
informed consent was obtained from all research participants.
Endotoxemia protocol. As previously described (16–18), healthy volunteers
aged 18–40 years and with BMI 18–30 kg/m
2 were recruited. Exclusions in-
cluded inﬂammatory disease, pregnancy, medication, substance, or supple-
ment use. Serial whole-blood samples were collected before and 2, 4, 6, 8, 12,
16, and 24 h following intravenous bolus of either 3 ng/kg (moderate dose) or
0.6 ng/kg (low dose) U.S. standard reference endotoxin (lipopolysaccharide
[LPS], lot no. CC-RE-LOT-1 + 2; Clinical Center, Pharmacy Department at the
National Institutes of Health, Bethesda, MD). Subcutaneous adipose samples
were collected by core needle aspiration through a 4-mm gluteal incision from
distinct sites 30 min before and 4, 12, and 24 h after LPS and stored at 280°C.
Adipose tissue studies. Adipose from lean (n = 11; BMI mean 24.3, 95% CI
22.5–26.1) subjects was obtained by aspiration biopsy as described above and
at bariatric surgery for obese patients (n = 13; BMI mean 48.3, 95% CI 43.0–
53.7). Samples were stored at 280°C for protein isolation. In a subset of lean
subjects (n = 8), a portion of the adipose was minced and digested immediately
with type I collagenase (Sigma-Aldrich, St. Louis, MO) for 1 h, centrifuged, and
mature adipocytes and stromal vascular fraction (SVF) were isolated.
Association study of CX3CR1 gene variants with metabolic traits. This
analysis in the University of Pennsylvania Coronary Artery Calciﬁcation Study
(PennCAC) sample focused on subjects of European ancestry recruited from
3 separate parallel community-based studies at UPenn: the Study of Inherited
Risk of Coronary Atherosclerosis (SIRCA; n = 799), the Penn Diabetes Heart
Study (PDHS; n = 782), and the Philadelphia Area Metabolic Syndrome Net-
work (PAMSyN; n = 480) (19). SIRCA is a cross-sectional study of factors
associated with CAC in asymptomatic nondiabetic subjects aged 30–75 years
and their families (20,21). PDHS is an ongoing, cross-sectional community-
based study of subjects aged 35–75 years with clinical type 2 diabetes (clinical
history of type 2 diabetes, use of oral hypoglycemic agents/insulin in a subject
older than age 40 years, or fasting blood glucose .126 mg/dL, 2-h postprandial
glucose .200 mg/dL, and no evidence of type 1 diabetes) (21,22). PAMSyN is
a cross-sectional study of nondiabetic subjects aged 18–75 years with one
or more metabolic syndrome risk factors (19). In all studies, known clinical
atherosclerotic cardiovascular disease (CVD) and overt kidney disease were
excluded. SIRCA, PDHS, and PAMSyN used the same clinical research center,
nursing staff, and research laboratories; these details and measurement
of biochemical and metabolic parameters have been described elsewhere
(19,21,23).
Case-control study of type 2 diabetes. An age- and gender-matched case-
control study of type 2 diabetes was selected from study resources at UPenn.
The diabetic subjects (n = 281) were selected randomly from the ongoing
PDHS described and referenced above. Age- and gender-matched nondiabetic
subjects (n = 274) were chosen from PAMSyN, also described above. Subjects
in this case-control study did not overlap with the genetic study above. Frozen
plasma samples, stored at 280°C, were used to assay CX3CL1 levels.
Cell culture
Primary human adipocytes. For the exploration of the cellular source of
CX3CL1, adipocyte and SVF of fresh human adipose tissue were prepared for
RNA and protein isolation as below. For in vitro experiments, preadipocytes
fromSVFwereisolated, cultured,anddifferentiated toadipocytes aspreviously
described (16). Brieﬂy, cells were grown to conﬂuence in oxidation fermen-
tation medium with 20% FBS and differentiated in serum-free medium with
high insulin and PPARg agonist (16,24). For assessment of inﬂammatory in-
duction of CX3CL1, mature adipocytes were washed and treated 6 100 ng/mL
LPS for 2, 4, 12, and 24 h (in triplicate for two independent experiments) or
cytokines (overnight 6 10 ng/mL tumor necrosis factor-a [TNF-a] and 5 ng/mL
interferon-g [IFN-g]; R&D Systems, Minneapolis, MN) with and without 24-h
pretreatment with PPARg agonist at 10 mmol/L concentration (GW347845;
gift from GlaxoSmithKline, King of Prussia, PA).
Human monocytes. As described (16,18), human monocytes were isolated
from healthy donor blood following apheresis and elutriation at the UPenn
Center for AIDS Research. These cells, as well as the monocytic THP-1 cell
line (American Type Culture Collection, Manassas, VA) were grown in RPMI-
1640 (Cambrex Bio Science, Verviers, Belgium) supplemented with 10% FBS
and 1% penicillin/streptomycin. To promote differentiation to macrophages,
cells were then supplemented with 100 ng/mL macrophage-colony stimulating
factor (Sigma, St. Louis, MO) for 7 days.
Adipocyte-monocyte adhesion assay. Fully differentiated human adipocytes
were washed and placed in Dulbecco’s modiﬁed Eagle’s medium/F12 + 0.5%
BSA. THP-1 monocytes were washed and resuspended in PBS, labeled with
calcein (Invitrogen, Carlsbad, CA) 15 ml/mL for 30 min, and then washed twice
before plating 2 3 10
5 cells per well of adipocytes (also grown at approxi-
mately 2 3 10
5 cells per well). Anti-CX3CL1, anti–MCP-1, both anti-CX3CL1
and anti–MCP-1 (all from R&D Systems), or control antibody (rabbit IgG) were
added to each well at a concentration of 20 mg/mL. Cells were incubated to-
gether at 37°C for 2 h after which they were washed three times with PBS.
Adherent cells were immediately counted under a ﬂuorescent microscope
with ﬁve random high power ﬁelds per well and four wells per condition. The
experiment was performed three times, on three different days, using the same
THP-1 and human adipocyte lines.
Laboratory methods
RNA extraction, cDNA synthesis, and quantitative PCR. Whole adipose
tissue was homogenized or for in vitro experiments, adipocytes and monocytes
were washed and lysed for RNA isolation using TRIzol reagent (Invitrogen).
RNA (500 ng) was reverse transcribed to cDNA using the High-Capacity cDNA
Archive Kit (ABI, Foster City, CA). Expression of genes was determined by
quantitative real-time PCR (7900 Real-Time PCR System; ABI) using TaqMan
Universal PCR MasterMix and primers and probes from Applied Biosystems.
To control for between-sample differences, mRNA levels were normalized to
b-actin for each sample by subtracting the Ct for b-actin from the Ct for the
gene of interest, producing a DCt value. The DCt for each posttreatment
sample was compared with the mean DCt for all pretreatment samples in
a single individual or experiment using the relative quantitation 2
-DDCt method
to determine fold change from baseline (25).
Protein extraction, ELISA, and Western blotting. Whole adipose tissue
was placed in radioimmunoprecipitation assay (RIPA) buffer, homogenized,
and protein concentration quantiﬁed using Pierce bicinchoninic acid kit
(Thermo Fisher Scientiﬁc, Rockford, IL). Samples then were diluted with
additional RIPA buffer to equal concentrations (1.5 mg/mL). Primary adipo-
cytes, stromal vascular cells, and cultured adipocytes were lysed for protein
extraction with RIPA buffer 3 30 min at 4°C; cell media was collected im-
mediately and frozen. Human CX3CL1 ELISA (R&D Systems; Minneapolis,
MN) was performed in duplicate according to manufacturer instructions. If
duplicates had .10% coefﬁcient of variation (CV), the sample was repeated.
Intra- and interassay CV were 5.7% and 5.3%. The lower and upper limits of
detection of the ELISA were 0.156 ng/mL and 10 ng/mL.
For Western blotting, monocytes, macrophages, and adipocytes were lysed
and protein quantiﬁed as above. Equal concentrations (20 mg) of lysate was
reduced, separated by SDS-PAGE electrophoresis, transferred to nitrocellu-
lose membranes, and blocked in 5% milk in TBS-tween prior to overnight in-
cubation (at 4°C) with 1:1000 dilution of CX3CR1 antibody (R&D Systems).
Blots were washed in Tris-buffered saline (TBS)-tween, incubated with rabbit
anti-goat secondary antibody (BioRad), and visualized by chemiluminescence.
The blots were stripped with stripping buffer (Pierce Endogen, Rockford, IL)
and reincubated using the same protocol as above with 1:5000 b-actin anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA).
Genotyping and quality control. A total of 2,096 Caucasian PennCAC study
participants were genotyped using the HumanCVD BeadChip V2 (Illumina, San
Diego, CA), which includes ;50,000 single nucleotide polymorphisms (SNPs)
within ;2,000 CVD candidate genes (26). Chip genotype calls were generated
with the cluster ﬁle provided by Illumina BeadStudio software. Individuals
with call rates less than 95% were excluded. SNPs with a low call rate (,95%)
were excluded. Recently, Sirois-Gagnon et al. (27) showed that two SNPs
(rs3732378 and rs3732379) in CX3CR1 were associated with obesity traits in
900 French Canadians. Therefore, we examined the association of rs3732378
and rs3732379 with multiple obesity-related and metabolic traits in PennCAC
(19). The call rates for rs3732378 and rs3732379 were 100%. The observed
distribution of genotypes did not deviate signiﬁcantly from Hardy-Weinberg
equilibrium.
Statistical analysis. Continuous variables were compared using Student t test
or the Mann-Whitney U test depending on whether normality could be as-
sumed. Fisher exact test was used for proportions. Unless otherwise speciﬁed,
data are reported as mean 6 SD. Geometric means of the independent repli-
cated samples and 95% CIs were used to estimate the fold change in mRNA for
the RT-PCR data. To assess differences among time points and between
groups, our analysis of CX3CL1 protein levels in adipose and cells used
repeated-measures ANOVA with a Bonferroni correction for multiple post hoc
comparisons. One-way ANOVA was used to assess differences in monocyte
adhesion to adipocytes in adhesion assay.
The rs3732378 and rs3732379 SNPs in CX3CR1 were tested for association
in the PennCAC sample using linear regression for quantitative traits and lo-
gistic regression for binary phenotypes with genotype included as an in-
dependent variable, coded as an additive genotype effect, with age, sex, and
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(http://pngu.mgh.harvard.edu/purcell/plink/) (28).
The association of CX3CL1 with type 2 diabetes was examined using logistic
regression, adjusting for covariates, including medication use and other car-
diometabolic risk factors with known or suspected inﬂuence on fractalkine
levels, as described in RESULTS. AnalyseswereperformedusingStata 10(StataCorp
LP, College Station, TX).
RESULTS
Inﬂammation upregulates CX3CL1 in human adipose
in vivo. Moderate dose (3 ng/kg) and low dose (0.6 ng/kg)
endotoxin increased adipose (Fig. 1A and B) as well as
blood (Fig. 1C) CX3CL1 in vivo. At 4 h, adipose tissue
CX3CL1 mRNA increased by 33-fold (95% CI 26.8–39.9, P ,
1 3 10
25) with 3 ng/kg LPS and 13-fold (95% CI 4.9–31.6,
P , 0.0001) with 0.6 ng/kg LPS (Fig. 1A). Adipose CX3CL1
protein levels increased at 4 h by over 40-fold (0.040 6
0.127 to 1.733 6 1.197 ng/mL, P = 0.006) and eightfold
(0.152 6 0.121 to 1.254 6 0.870 ng/mL, P = 0.004), re-
spectively, with 3 ng/kg and 0.6 ng/kg LPS (Fig. 1B).
Adipose CX3CL1 is increased in human obesity, and
CX3CL1 is secreted by primary human adipocytes.
Levels of CX3CL1 protein in subcutaneous adipose were
signiﬁcantly higher in obese (n = 13) compared with lean
(n = 11) subjects (0.420 6 0.387 vs. 0.228 6 0.187 ng/mL, P =
0.04) (Fig. 2A). In adipose of obese subjects undergoing
bariatric surgery (n =1 3 ) ,C X 3 C L 1l e v e l sw e r eh i g h e ri n
visceral than subcutaneous adipose (0.736 6 0.308 vs.
0.420 6 0.387 ng/mL, P = 0.01) (Fig. 2B); depot levels were,
however, correlated with each other (Spearman r =0 . 9 1 ) .
In fractionated subcutaneous adipose, CX3CL1 mRNA
was expressed, as expected (8), in the SVF but was also
detected in the adipocyte fraction (Fig. 2C); protein levels
were also present in both fractions (Fig. 2D). In contrast,
mRNA for CX3CR1, the fractalkine receptor, was expressed
only in SVF (DCt [cycle threshold] = 6.2 relative to b-actin
mRNA) but not in adipocytes (Ct levels .40). CX3CR1 pro-
tein was present at Western blotting in human monocytes
and macrophages, but was undetectable in adipocytes
(Supplementary Fig. 1).
Inﬂammatory regulation of CX3CL1 in human adipo-
cytes in vitro. The presence of CX3CL1 in the isolated
adipocyte fraction of human adipose prompted us to ex-
amine CX3CL1 regulation in human adipocytes in vitro.
CX3CL1 mRNA (DCt 8.6 relative to b-actin mRNA) and
secreted protein (0.566 6 0.345 ng/mL/24 hr) were present
in unstimulated cultured human adipocytes. LPS treatment
(100 ng/mL) increased CX3CL1 mRNA (45-fold at 4 h, P ,
0.0001) (Fig. 3A) and secreted protein (peak 2.587 6 0.937
ng/mL, P , 0.01 for each) (Fig. 3B). Combined treatment
with TNF-a and IFN-g also markedly increased CX3CL1
mRNA (27.5-fold at 12 h, P = 0.006) and protein (0.565 6
0.3445 to 1.767 6 0.483 ng/mL, P = 0.007). Pretreatment of
human adipocytes with a PPAR-g agonist GW347845 10
mmol/L for 24 h completely attenuated TNF-a/IFN-g in-
duction of CX3CL1 (Fig. 3C and D).
CX3CL1-CX3CR1 mediate monocyte adhesion to hu-
man adipocytes. CX3CL1, through its membrane-anchored
form, promotes adhesion and retention of leukocytes to en-
dothelial cells (29), but its effect on adipocyte-monocyte
interactions has not been reported. CX3CL1 blocking anti-
body reduced human monocyte adhesion to human adipo-
cytes by almost 50% (75 6 37 vs. 121 6 74 cells/high-powered
ﬁeld [HPF], P , 0.0001) (Fig. 4A and C), similar to the
effects of MCP-1 blocking antibody (Fig. 4A and D). Com-
bined antibody blockade of CX3CL1 and MCP-1 showed an
additive attenuation of monocyte adhesion to adipocytes
(58 6 26 cells/HFP, P , 0.0001 vs. control, P , 0.005 vs.
CX3CL1 antibody alone, and P = 0.04 vs. MCP-1 antibody
alone) (Fig. 4A and E).
Genetic variation in CX3CR1 is associated with meta-
bolic traits in humans. Two common nonsynonymous
coding SNPs in CX3CR1 rs3732378 (T280M) and rs3732379
(V249I), which are in moderate linkage disequilibrium (r
2 =
0.66 in 1000 Genomes Pilot 1 publically available dataset),
are related to several disease traits in human (8) including
a recent association with obesity in French Canadians
(27). McDermott et al. (30) showed that rs3732378 (T280M)
has functional impact on human monocyte migration, ad-
hesion, and activation.
Demographic and metabolic characteristics of the
PennCAC sample are presented in Supplementary Table 1.
Consistent with the ﬁndings of Sirois-Gagnon et al., individ-
uals in PennCAC with the A allele at rs3732378 or rs3732379
tended to have greater waist circumference and higher levels
of homeostasis model assessment of insulin resistance and
leptin but lower levels of adiponectin (Table 1). Further,
these alleles tended toward association with both NCEP-
deﬁned (31) metabolic syndrome and type 2 diabetes.
Plasma CX3CL1 levels are increased in type 2 di-
abetes. In order to further explore the association of
CX3CL1 with a clinically important obesity-related disease
FIG. 1. Adipose tissue and circulating CX3CL1 levels are increased in
human endotoxemia. Adipose tissue relative mRNA expression (A) and
protein levels (B) were increased by both 3 ng/kg and 0.6 ng/kg endo-
toxin. C: Plasma levels were also increased by both endotoxin doses.
Closed circles and solid line denote 3 ng/kg endotoxin; open circles and
dashed line denote 0.6 ng/kg endotoxin. Values shown are mean 6 SD.
*P < 0.001; **P < 0.0001 compared with pre-endotoxin (time 0) levels.
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study of plasma CX3CL1 in type 2 diabetes. Supplementary
Table 2 presents baseline clinical characteristics for the
age- and sex-matched case-control sample. As expected,
there were differences in several clinical and biochemical
measures as well as medication use between patients with
diabetes and nondiabetics. Diabetic subjects had greater
use of statins and ACE-inhibitors and were using insulin,
metformin, and thiazolodinediones. Levels of CX3CL1 strati-
ﬁed by demographic, metabolic parameters, and medications
FIG. 2. Adipose CX3CL1 is increased in obesity and is present in both the primary adipocyte fraction and the SVF. A: Obese human subjects (n = 13)
had signiﬁcantly higher CX3CL1 protein in subcutaneous adipose tissue than lean human subjects (n = 11). B: In obese subjects (n = 13), there was
increased CX3CL1 protein in visceral compared with subcutaneous adipose tissue. In lean human adipose (n = 8), both the adipocyte and the SVFs
expressed CX3CL1 mRNA (C) and protein (D). Values shown are mean 6 SD. *P < 0.05 between groups.
FIG. 3. Regulation of CX3CL1 expression in human adipocytes by inﬂammation and PPAR-g. Endotoxin (100 ng/mL) upregulated CX3CL1 relative
mRNA expression (A) and secreted protein (B) in fully differentiated cultured human adipocytes. Similar upregulation was seen after stimulation
with 10 ng/mL TNF-a and 5 ng/mL IFN-g in CX3CL1 mRNA (C) and protein (D); the inﬂammatory stimulation was ablated completely by pre-
treatment of adipocytes with 10 mMP P A R - g agonist GW347845 (representative experiment with n = 3 replicates). Values shown are means 6 SD.
*P < 0.01; **P < 0.01; ***P < 0.0001 compared with control levels.
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ferences in CX3CL1 levels among these parameters or across
strata of diabetic medications (Supplementary Table 4).
Plasma CX3CL1 was signiﬁcantly higher in patients with
diabetes than in nondiabetics (0.506 6 0.262 ng/mL vs.
0.422 6 0.210 ng/mL, P , 0.0001) (Fig. 5). In unadjusted
analysis, there was more than a twofold increased odds
ratio for diabetes for a 1 SD (0.21 ng/mL) increase in plasma
CX3CL1 concentration; this remained signiﬁcant after
adjusting for BMI, ethnicity, and multiple other metabolic
risk factors (Table 2).
DISCUSSION
We have identiﬁed CX3CL1 as a novel adipose tissue che-
mokine in humans. First, adipose CX3CL1 is increased in
obesity as well as in evoked adipose inﬂammation. Second
CX3CL1, which is secreted by adipocytes and adipose SVF,
promotes monocyte adhesion to human adipocytes. Third,
the association of genetic variation in CX3CR1 with mul-
tiple metabolic traits and the ﬁnding of higher levels of
CX3CL1 in type 2 diabetes provide support for clinical
relevance. Thus, CX3CL1 may modulate recruitment of
leukocytes in clinical syndromes of adipose inﬂammation
and represent a novel therapeutic target for obesity and
type 2 diabetes.
Several inﬂammatory signaling pathways have been
implicated in adipose dysfunction and insulin resistance.
In particular, adipose recruitment and activation of mac-
rophages and T-cells play a proximal role in obesity and
insulin resistance (2,3,32). However, the speciﬁc signals
that initiate recruitment of leukocytes to adipose and their
activation are unclear, particularly in humans.
We discovered CX3CL1 as a novel adipochemokine in-
duced in human adipose using experimental endotoxemia.
Although an acute model, endotoxemia-induced metabolic
perturbations (17,18,33,34) are of speciﬁc relevance to
chronic changes in diet-induced obesity, insulin resistance,
and metabolic syndrome (16,35). For example, endotox-
emia induces insulin resistance in humans (17,34) with
adipose inﬂammation preceding loss of insulin sensitivity
(17). Further, ablation of Toll-like receptor-4 (TLR4), the
receptor for endotoxin, in high-fat–diet fed mice attenuates
obesity and improves metabolic traits (36–38). Recent work
demonstrates that certain dietary and adipocyte fatty acids
are endogenous TLR4 ligands (36) and high-fat diets in-
crease plasma LPS and mononuclear cell TLR signaling (39).
Inﬂammatory induction of CX3CL1 in adipose, there-
fore, raises the possibility of its involvement in the path-
ogenesis of insulin resistance and type 2 diabetes. Indeed,
emerging data implicates CX3CL1 as a unique chemokine
in human disease. The soluble form of CX3CL1, cleaved from
the membrane by the enzyme ADAM17 or TACE (TNF-a
converting enzyme), may be involved in chemotaxis, while
the membrane-anchored form promotes adhesion and re-
tention of leukocytes (40). CX3CL1 modulates monocyte
and T-cell recruitment and adherence to endothelium in
several chronic inﬂammatory diseases including athero-
sclerosis in both rodents (15,41) and humans (30,42). Ex-
perimental studies also suggest that therapeutic blockade
of CX3CL1-CX3CR1 may produce fewer side effects than
other chemokines because CX3CL1-CX3CR1 play a limited
role in homeostasis or acute inﬂammation (43,44).
Whether CX3CL1-CX3CR1 modulates inﬂammatory
monocyte recruitment to adipose is unknown. Recent work,
however, is suggestive; adipose tissue macrophages in
obese adipose express high levels of CX3CR1 (45). We
demonstrate that obese human adipose secreted greater
amounts of CX3CL1 than lean adipose. Compared with
subcutaneous fat, visceral adipose, known to have greater
FIG. 4. CX3CL1 modulates adhesion of human monocytes to primary
human adipocytes. A:M e a nn u m b e r( 6 SD) of ﬂuorescent THP-1 mono-
cytes adherent to primary adipocytes were counted per HPF in each
experimental condition. The groups designated for each block refer to
blocking antibodies used in the condition. *P < 0.0001 compared with
negative antibody; **P < 0.005 compared with CX3CL1 alone. Repre-
sentative images for negative antibody (B), CX3CL1 antibody (C),
M C P - 1a n t i b o d y( D), and both CX3CL1 and MCP-1 antibodies (E)a r e
shown. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
TABLE 1
Association of CX3CR1 polymorphisms rs3732378 and rs3732379 with metabolic traits in PennCAC













— n = 2073 n = 1209 n = 1336 n = 1336 n = 2077 n = 2095
rs3732378 (T280M) G/A (A) 0.18 0.50 (0.03) 0.13 (0.003) 0.08 (0.03) 20.08 (0.02) 1.20 (0.03) 1.20 (0.05)
rs3732379 (V249I) G/A (A) 0.29 0.38 (0.06) 0.09 (0.02) 0.05 (0.09) 20.07 (0.03) 1.13 (0.10) 1.15 (0.08)
Results are shown as b and P values for linear regression and odds ratios (ORs) and P values for logistic regression for minor allele as the risk
allele using an additive model adjusted for age, sex, and smoking status. Waist, waist circumference; HOMA-IR, homeostasis model assess-
ment of insulin resistance; Met syn, National Cholesterol Education Program–deﬁned metabolic syndrome; T2D, type 2 diabetes.
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levels. Consistent with literature demonstrating the endo-
thelium as a source of CX3CL1 (12), the SVF of adipose
secreted CX3CL1. The adipocyte fraction, however, also
expressed CX3CL1 with marked induction by adipocyto-
kines (TNF-a and IFN-g), which are upregulated and im-
plicated in obesity. Given the fundamental role of PPAR-g
in adipocyte differentiation and healthy function, suppres-
sion of this phenomenon by a PPAR-g agonist is consistent
with a role of CX3CL1 in early adipose inﬂammation and
adipocyte dysregulation in obesity and insulin resistance.
Thus, both adipocytes and SVFs may secrete CX3CL1 and
modulate leukocyte recruitment to adipose in obesity.
Like others (34), we found that CX3CR1 is highly expressed
on primary human monocytes and THP-1 monocytes. Using
blocking antibodies, we found that THP-1 monocyte adher-
ence to human adipocytes is CX3CL1-CX3CR1–dependent.
Several groups recently showed independent and additive
effects of CX3CL1-CX3CR1 and CCR2 in atherosclerosis
(12,47). Remarkably, our preliminary data also show ad-
ditive effects of CX3CR1 and CCR2 pathways in monocyte-
adipocyte interactions raising the possibility that these
chemokines may have independent, nonredundant actions
in leukocyte recruitment to adipose in obesity. Whether
this is true in the pathogenesis of insulin resistance and
type 2 diabetes in vivo remains to be established.
In humans, variation in CX3CR1 has been related to
monocyte chemotactic function (30) and atherosclerotic
CVD (48). Recently, Sirois-Gagnon et al. found the asso-
ciation of SNPs in CX3CR1 with obesity. We replicated and
extended these ﬁndings by showing the association of these
SNPs with multiple metabolic traits including metabolic
syndrome and type 2 diabetes. Finally, our case-control
study found higher CX3CL1 levels in type 2 diabetic sub-
jects compared with control subjects. These data extend
our experimental ﬁndings by suggesting potential associ-
ations of CX3CL1-CX3CR1 with clinically relevant meta-
bolic traits and disease.
Conclusion. CX3CL1-CX3CR1 is a novel adipochemokine
system in humans. Its expression in obese adipose, inﬂam-
matory upregulation in adipose and adipocytes, modulation
of monocyte-adipocyte interactions, and association with
human disease traits suggest a role in clinical syndromes of
adipose inﬂammation and its potential as a novel thera-
peutic target in obesity and type 2 diabetes. Future studies
in rodents with gene deﬁciency and humans using phar-
macological modulation are required to deﬁne the causal
role of CX3CL1-CX3CR1 in adipose inﬂammation, insulin
resistance, and type 2 diabetes.
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